| Shingo Baba | Last modified date：2022.06.23 |
Graduate School
Undergraduate School
E-Mail *Since the e-mail address is not displayed in Internet Explorer, please use another web browser:Google Chrome, safari.
Homepage
https://kyushu-u.pure.elsevier.com/en/persons/shingo-baba
Reseacher Profiling Tool Kyushu University Pure
Academic Degree
MD、PhD
Country of degree conferring institution (Overseas)
No
Field of Specialization
Radiology
Total Priod of education and research career in the foreign country
02years00months
Outline Activities
1) Education
I perform lectures on clinical nuclear medicine as bedside training for medical students. In addition, I teach the basic clinical work such as examination, medical history, charting, ordering tests, interpretation of results, understanding of pathophysiology of diseases, and explanation to patients and their families in the examination of patients as attending physicians together with residents and graduate students.
2) Research
We are conducting various clinical studies in the field of nuclear oncology using positron emission tomography (PET).
Especially for head and neck tumors, we are actively performing FDG-PET in combination with iodine therapy to compare the degree of differentiation of thyroid tumors and the degree of tracer accumulation.
We are also conducting research on amino acid metabolism in tumors using radionuclides produced by the in-house cyclotron.
3) Medical Care
At Kyushu University Hospital, we perform various nuclear medicine examinations, inject radionuclides, explain the examinations to patients, and evaluate (read) the results.
As an outpatient of the Radiology Department, I am engaged in the treatment of outpatients (consultations, treatments, appointments for examinations, hospitalization procedures, etc.).
In addition, as an attending physician for patients admitted to the Radiology Department, I provide medical care, treatment, and management of inpatients.
In particular, I am actively performing 131I internal medicine therapy for thyroid cancer and PRRT (peptide receptor nuclear medicine internal medicine therapy) using lutescium-117 for neuroendocrine tumors at the Isotope Therapy Center.
I perform lectures on clinical nuclear medicine as bedside training for medical students. In addition, I teach the basic clinical work such as examination, medical history, charting, ordering tests, interpretation of results, understanding of pathophysiology of diseases, and explanation to patients and their families in the examination of patients as attending physicians together with residents and graduate students.
2) Research
We are conducting various clinical studies in the field of nuclear oncology using positron emission tomography (PET).
Especially for head and neck tumors, we are actively performing FDG-PET in combination with iodine therapy to compare the degree of differentiation of thyroid tumors and the degree of tracer accumulation.
We are also conducting research on amino acid metabolism in tumors using radionuclides produced by the in-house cyclotron.
3) Medical Care
At Kyushu University Hospital, we perform various nuclear medicine examinations, inject radionuclides, explain the examinations to patients, and evaluate (read) the results.
As an outpatient of the Radiology Department, I am engaged in the treatment of outpatients (consultations, treatments, appointments for examinations, hospitalization procedures, etc.).
In addition, as an attending physician for patients admitted to the Radiology Department, I provide medical care, treatment, and management of inpatients.
In particular, I am actively performing 131I internal medicine therapy for thyroid cancer and PRRT (peptide receptor nuclear medicine internal medicine therapy) using lutescium-117 for neuroendocrine tumors at the Isotope Therapy Center.
Research
Research Interests
Membership in Academic Society
- Development of a program for automatic detection of abnormal accumulation in FDG-PET images using machine learning
keyword : FDG-PET AI deep learning
2021.06～2022.11. - Assessment of malignancy and prognosis of tumor using volume-metric parameter of the PET
keyword : PROGNOSIS PET MTV TLG
2015.04～2017.05. - development of novel receptor imaging using 64Cu labeled antibody
keyword : Cu64 PET Antibody imaging
2015.04～2017.05. - Variability of size-collected pretreatment FDG uptake predicts prognosis of patients with diffuse large cell lymphoma.
keyword : lymphoma FDG-PET
2013.05～2013.05. - Extrahippocampal benzodiazepin receptor density of hippocampal sclerosis correlates with surgical outcome.
keyword : BZR receptor density, Epilepsy
2010.03～2012.01. - Assessment of the FDG-PET findings and CT Hounsfield unit in the cases of lung nodules with GGO.
keyword : FDG-PET Lung cancer
2010.05～2012.05. - Usefulness of dynamic FDG PET/CT for the evaluation of liver tumor
keyword : PET/CT
2013.05～2013.05. - Diagnostic and Prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer; comparison with ADC form diffusion weighted MRI.
keyword : FDG-PET PET/CT
2007.10～2013.03.
- The programmed cell death-1 (PD-1) and programmed cell death-ligand-1 (PD-L1) signaling pathways are potent T-cell inhibitory pathways that cancer cells use to evade tumor control by host autoimmunity. Immune checkpoint inhibitors, which use antibodies to block this pathway, have been shown to have potent anti-tumor effects in some cancers.In Japan, nivolumab has been approved for the treatment of cancer. In Japan, nivolumab (Opdivo) was approved for the treatment of malignant melanoma that is not curatively resectable, followed by renal cell carcinoma, recurrent non-small cell carcinoma, and Hodgkin lymphoma.In Japan, nivolumab (Opdivo) was approved for the treatment of incurable malignant melanoma, followed by renal cell carcinoma, recurrent non-small cell carcinoma, Hodgkin lymphoma, and gastric cancer, and is likely to be rapidly expanded to other cancer types in the future. However, the drug is extremely expensive.However, this drug is not only extremely expensive, but also has a certain frequency of poor therapeutic effects and is known to cause serious side effects.Therefore, it is essential to establish an appropriate method for selecting patients who are expected to benefit from treatment. PD-L1 expression in tumors is a biomarker that predicts response to anti-PD-1/anti-PD-L1 therapy.Although direct immunostaining with biopsy has been the only method to evaluate PD-L1 expression, biopsy of all lesions is not feasible, especially for multiple lesions.
However, biopsy of all lesions is impractical, especially in patients with multiple metastases. However, biopsy of all lesions is not feasible, especially in patients with multiple metastases. In addition, PD-L1 expression may be heterogeneous in multiple lesions within the same individual and may change dynamically with treatment.Therefore, it is desirable to establish a non-invasive evaluation method. Recently, a method to image PDL1 expression using positron emission tomography has been reported.The purpose of this study is to prepare 18F-PD-L1, which is labeled with 18F, and to apply it clinically through animal experiments. Since it is a new tracer, there are few reports of clinical studies.Since it is a new tracer, there have been few reports of clinical studies, and its clinical usefulness has not yet been confirmed, so the results of clinical studies are awaited at an early stage. In this fiscal year, we constructed a facility for the synthesis of radionuclides suitable for antibody labeling and prepared for the synthesis. - To demonstrate the usefulness of FDG-PET/CT for the diagnosis of fever of unknown origin (FUO), we will compare the sensitivity of FDG-PET/CT and that of gallium SPECT for the detection of fever origin.
- The purpose of this study is to evaluate the usefulness of 11C-PIB PET in the differential diagnosis of Alzheimer's type dementia. We evaluate the relationship between 11C-PIB PET avidity and change of cognitive function.
- Inclusion criteria: 1.Newly diagnosed NHL by tissue biopsy; DLBCL, listed under mature B-cell neoplasms according to the WHO classification (diffuse large B-cell lymphoma/NOS, primary mediastinal large B-cell lymphoma, excluding intravascular large B-cell lymphoma). 2.Histologically proven CD20 positive DLBCL. 3.Patients with measurable disease by CT scan. 4.Age: 15-65. 5.Ann Arbor stage: 2-4. 6.Performance status (ECOG): 0-3. 7.Age-adjusted International Prognostic Index (aaIPI): High or High-intermediate. 8.Adequate hematological, hepatic, renal, cardiac, or pulmonary function (Neutrophil count >=1000/mm3, Platelet count >=7.5X104/mm3, AST<=3 X upper limit of normal, ALT<=3 X upper limit of normal, T. Bil<=2.0mg/dL, Cr<=2.0mg/dL, EF>=50%, PaO2>=60 mmHg or SaO2>=90%). 9.Patients without severe complications. 10.The patient must sign the consent form prior to registration. If the patient is under age, both the guardian and the patient must sign the consent form.
Exclusion criteria: 1.Patients with a history of prior or concurrent malignancies. 2.Patients who are on any medication for diabetes. 3.Patients who have severe complications such as active systematic infection, heart failure, respiratory failure, pulmonary disease, hepatic failure, liver cirrhosis, acute or chronic hepatitis, renal failure, active tuberculosis. 4.Patients with a history of angina or cardiac infarction. Patients with cardiomyopathy. Patients taking anti-arrhythmic drugs. 5.Patients with a history of drug anaphylaxis. 6.Patients with severe mental illness. 7.Patients with a history of lymphoma, leukemia, or MDS. 8.Patients with a history of chemotherapy, cytokine therapy, or antibody therapy for present DLBCL. 9.Patients with primary central nervous system lymphoma or with central nervous system involvement of DLBCL 10.Pregnancy or lactation. 11.Known hepatitis B or C virus infection 12.Known HIV or HTLV-1 infection 13.Patients with any medical condition that in the opinion of the investigator would compromise treatment delivery.
Papers
Presentations
| 1. | Yasuhiro Maruoka, Shingo Baba, Takuro Isoda, Yoshiyuki Kitamura, Masayuki Sasaki, Kousei Ishigami, Prognostic value of FDG-PET residual metabolic activity after initial 131I therapy for differentiated thyroid carcinoma with bone metastasis, Society of Nuclear Medicine and Molecular Imaging ,Annual Meeting 2022, 2022.06. |
| 2. | Yoshiyuki Kitamura, Shingo Baba, Takuro Isoda, Yasuhiro Maruoka, Takeo Fujino, Masayuki Sasaki, Kousei Ishigami, Usefulness of FDG-PET/CT for diagnosis of myocardial rejection after heart transplantation, Society of Nuclear Medicine and Molecular Imaging ,Annual Meeting 2022, 2022.06. |
| 3. | Establishment of automated tumor segmentation of whole-body FDG-PET using 3D U-net. |
| 4. | Shingo Baba, Takuro Isoda, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Kousei Ishigami, Role of 18F-FDG PET/CT as a predictor of eradication of Helicobacter pylori in the patients with early-stage gastric B cell lymphoma, Society of Nuclear Medicine and Molecular Imaging ,Annual Meeting 2021, 2021.06, [URL]. |
| 5. | Relationship between the visualization of the lesion and uptake time of 131NaI. |
| 6. | Takuro Isoda, Shingo Baba, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Akihiro Nishie, Kousei Ishigami, 131I / 18FDG Flip-Flop Phenomenon in the Bone Metastasis from Differentiated Thyroid Cancer, Society of Nuclear Medicine and Molecular Imaging ,Annual Meeting 2020, 2020.07, Objectives: Radioiodine therapy is used to treat distant metastases from thyroid cancer. A reverse relationship between iodine and FDG accumulation is found in thyroid cancer lesions, the so-called “flip-flop” phenomenon. The aim of this study was to assess the relationship between iodine and FDG uptake in bone metastasis lesions from thyroid cancer.Methods: The cases of 20 patients who underwent radioiodine therapy for bone metastasis were studied retrospectively (age, 27-74 yrs; median, 62 yrs; males : females, 6 : 14). Iodine uptake was evaluated visually and the lesions showing iodine uptake more than background were determined as positive. FDG uptake was assessed using SUVmax. We compared FDG uptake between the lesions with (n=19) and without (n=88) iodine uptake in bone metastasis.Results: The bone metastasis lesions without iodine showed significantly higher FDG uptake than those with iodine uptake (p < 0.0001). However, the degree of FDG uptake in bone metastasis lesions was also relatively high (Median of SUVmax: 4.64). Thirty-nine out of 88 iodine-positive bone metastasis lesions (44.3 %) showed more than 5 of SUVmax. On the other hand, only one iodine-positive lesion (1.1 %) showed more than 10 of SUVmax, while 9 out of 19 (47.4 %) iodine-negative lesions did.Conclusions: Bone metastasis lesion from thyroid cancer not showing iodine uptake showed higher FDG uptake compared to those with iodine uptake. On the other hand, more than 40 % of bone metastasis lesions with iodine uptake showed relatively high FDG uptake (SUVmax>5). Enormously high degree of FDG uptake (SUVmax>10) was rare in the lesions with iodine uptake, while it was common in those without iodine uptake.. |
| 7. | Shingo Baba, Takuro Isoda, Yoshiyuki Kitamura, Ryo Somehara, Akio Hiwatashi, Saiji Ohga, Nobuhiro Hata, Hiroshi Honda, Comparison of visual and semiquantitativeanalysis of C-11 Methionine PET/CT for the differentiation of recurrent brain tumors from radiation necrosis after radiotherapy, Society of Nuclear Medicine and Molecular Imaging ,Annual Meeting 2019, 2019.07, Background C-11Methionine positron emission tomography has reported to be useful to distinguish brain tumor recurrence from radiation necrosis. We undertook this study to directly compare visual and semiquantitative analysis for the evaluation of recurrence in brain tumors. Method Thirty-nine patients with a history of treated brain tumors (32 primary brain tumor and 7 metastatic tumor) referred for evaluation of recurrent disease were initially included in the study. There were 24 males and 15 females (mean age: 39.1. ± 15.4 years; range: 15 to 69 years). All patients are suspected recurrence, persistence, or necrotic post-therapeutic changes and underwent the MET PET/CT study. Visual image interpretation was performed independently by 2 PET physicians using the fused PET/CT images. Images were also analyzed semiquantitatively using ratio of SUVmax of tumor and normal contralateral white matter (T/Nw) and grey matter (T/Ng). Imaging results were compared with histopathology on tumor excision or biopsy in 12 patients and with clinical follow-up in 27 patients. Results The final diagnosis was tumor recurrence in 28 patients and no recurrence/stable disease in 11 patients. Visual analyses were positive in 25 (64.1%) and negative in 9 (35.9%). The sensitivity, specificity and accuracy were 82.1%, 81.8% and 82.1% respectively. For the semiquantitative analysis, positive cases were seen in 26 (66.7%) (TNw) and 25 (64.1%) (TNg). The sensitivity, specificity and accuracy were [89.3(TNw); 85.7(TNg)], [90.9(TNw); 90.9(TNg)] and [89.7(TNw); 87.2(TNg)] respectively. Highest AUC of 0.93 was seen in TNw using the cut-off value of 1.95. There was no statistically significant differences among three methods. Conclusion Although, it was a slight difference, diagnostic performance using semiquantitative analysis using T/Nw was the best among the three method used in this study. MET-PET/CT was a useful technique to differentiate post-therapeutic changes from tumor presence in treated patients with brain tumor in whom diagnosis was nonconclusive. . |
| 8. | Shingo Baba, Takuro Isoda, Yoshiyuki Kitamura, Clinical Impact of radiolabeled amino acid PET for the diagnosis of cerebral gliomas, THE 13TH ASIA OCEANIA CONGRESS OF NUCLEAR MEDICINE AND BIOLOGY, 2019.05, BACKGROUND: Magnetic resonance imaging (MRI) is the investigation of choice for diagnosing cerebral glioma, but its capacity to differentiate tumor tissue from non-specific tissue changes is limited. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a molecular imaging technique, which provides information on the metabolic behavior of the tumor. However, FDG-PET often leads to several controversies in making clinical decisions due to their high uptake of normal surrounding tissues, and pose difficulty in delineating treatment-induced necrosis, edema, inflammation, and pseudoprogression. Thus, it is imperative to find new approach to demarcate normal and tumor tissues. PET using radiolabeled amino acids is a promising technique and it increases diagnostic accuracy for brain tumor. PURPOSE: We have provided some cases and literature of 11C methionine-PET (MET-PET) and other amino acid PET for gliomas, along with prognostic and diagnostic significance. METHODS: Review based on the authors' own research results and a selective literature review RESULTS: The use of radiolabeled amino acids allows better delineation of tumor margins and improves targeting of biopsy and radiotherapy, and planning surgery. In addition, amino acid imaging appears useful in distinguishing tumor recurrence from non-specific post-therapeutic necrosis, in predicting prognosis in low grade gliomas, and in monitoring metabolic response during treatment. CONCLUSION: Amino acid PET including MET-PET can lead to a better understanding of the existing controversies and can enhance our knowledge for future treatment of GBM patients based on their tumor gene signatures to achieve better prognosis and treatment outcome.. |
| 9. | Effect of spatial resolution on the PET Radiomics parameters of malignant tumors. |
| 10. | Shingo Baba, Takuro Isoda, Yoshiyuki Kitamura, Ryo Somehara , Keiichiro Tahara, Akio Hiwatashi, Saiji Ohga, Koji Yshimoto, Hiroshi Honda, Comparison of F-18 FDG and C-11 Methionine PET/CT for the differentiation of recurrent brain tumors from radiation necrosis after radiotherapy, Society of Nuclear Medicine and Molecular Imaging (SNMMI), 2018.06, Background C-11Methionine positron emission tomography has reported to be useful to distinguish brain tumor recurrence from radiation necrosis. We undertook this study to directly compare F-18 flurodeoxyglucose (FDG) PET and C-11 methionine (MET) PET for the evaluation of recurrence in brain tumors. Method Thirty-seven patients with a history of treated brain tumors (31 primary brain tumor and 6 metastatic tumor) referred for evaluation of recurrent disease were initially included in the study. There were 22 males and 15 females (mean age: 38.7 ± 14.4 years; range: 15 to 65 years). All patients underwent the MET and FDG study within 2 weeks. Visual image interpretation was performed independently by 2 PET physicians for each tracer using the fused PET/CT images. Images were analyzed semiquantitatively using tumor to normal contralateral cortex ratios (T/N). Imaging results were compared with histopathology on tumor excision or biopsy in 10 patients and with clinical follow-up in 27 patients. Results The final diagnosis was tumor recurrence in 27 patients and no recurrence/stable disease in 10 patients. On FDG, findings in 23/37 (62.2%) were suggestive of recurrent tumors. On MET, findings in 28/37 (75.7%) cases were suggestive of recurrent tumors. Spatially separated secondary lesions were clearly delineated in 4 cases, 3 were glioblastoma multiforme (GBM) and 1 were anaplastic astrocytoma. Two of the secondary lesions were missed on FDG PET. Using a cutoff for T/N ratio on FDG of >0.90 to differentiate recurrence from no recurrence, sensitivity of FDG was 74.1%, whereas specificity was 70.0%. Area under the curve was 0.86. Using a cutoff for T/N ratio of >2.1 to differentiate recurrence from no recurrence, sensitivity of MET was 92.6%, whereas specificity was 80.0%. Area under the curve was 0.95. Conclusion Semiquantitative analysis of MET can provide more informative values than FDG to aid in the differentiation of tumor recurrence from radiation necrosis. . |
| 11. | Takuro Isoda, Shingo Baba, Yoshiyuki Kitamura, Ryo Somehara , Keiichiro Tahara,Taiki Higo, Takeo Fujino, Masayuki Sasaki, Hiroshi Honda, FDG-PET of drive line infection and non-pathological uptake in or around a ventricular assist device, Society of Nuclear Medicine and Molecular Imaging (SNMMI), 2018.06. |
| 12. | Yasuhiro Maruoka, Shingo Baba, Michinobu Nagao, Takuro Isoda, Kitamura Yoshiyuki, Keiichiro Tahara, Akihiro Nishie, Satoshi Kawanami, Abe Kohtaro, Kazuya Hosokawa, Masayuki Sasaki, Hiroshi Honda, Evaluation of Balloon Pulmonary Angioplasty Response for Chronic Thromboembolic Pulmonary Hypertension Using Fractal Analysis of 99mTc-MAA SPECT, 第56回日本核医学会学術総会, 2016.11. |
| 13. | Takuro Isoda, Shingo Baba, Yasuhiro Maruoka, Kitamura Yoshiyuki, Keiichiro Tahara, Masayuki Sasaki, Hiroshi Honda, Use of recombinant human thyroid-stimulating hormone (rhTSH) reduces the damage to salivary glands after radioiodine therapy for thyroid cancer, 63th Annual Meeting, Society of Nuclear Medicine, 2016.06. |
| 14. | Kitamura Yoshiyuki, Shingo Baba, TAKURO ISODA, Yasuhiro Maruoka, Keiichiro Tahara, Masayuki Sasaki, Akihiro Nishie, Hiroshi Honda, Relationship of the I-123 Metaiodobenzylguanidine (MIBG) Uptake and Early Relapse of Neuroblastoma Using Semi-quantitative Analysis of SPECT/CT., 63th Annual Meeting, Society of Nuclear Medicine, 2016.06. |
| 15. | Yasuhiro Maruoka, Shingo Baba, Michinobu Nagao, Takuro Isoda, Kitamura Yoshiyuki, Keiichiro Tahara, Akihiro Nishie, Satoshi Kawanami, Abe Kohtaro, Kazuya Hosokawa, Masayuki Sasaki, Hiroshi Honda, Evaluation of Balloon Pulmonary Angioplasty Response for Chronic Thromboembolic Pulmonary Hypertension Using Fractal Analysis of 99mTc-MAA SPECT, 63th Annual Meeting, Society of Nuclear Medicine, 2016.06. |
| 16. | Shingo Baba, Yuji Watanabe, TAKURO ISODA, Yasuhiro Maruoka, Yoshiyuki Kitamura, Keiichiro Tahara, Koji Sagiyama, Ryotaro Kamei, Hiroshi Honda, Evaluation of the novel method for the measurement of brain amyloid burden using PET/MRI, 第55回日本核医学会学術総会, 2015.10. |
| 17. | Shingo Baba, TAKURO ISODA, Yasuhiro Maruoka, Yoshiyuki Kitamura, Koji Sagiyama, Ryotaro Kamei, Yuji Watanabe, Hiroshi Honda, Evaluation of cortical uptake of amyloid PET tracer with hybrid PET/MRI; comparison with PET/CT, 62th Annual Meeting, Society of Nuclear Medicine, 2015.06. |
| 18. | Shingo Baba, TAKURO ISODA, Yasuhiro Maruoka, Yoshiyuki Kitamura, KojI Kato, Masayuki Sasaki, Hiroshi Honda, Usefulness of FDG-PET/CT in the diagnosis of acute transformation of Adult T-cell Lymphoma, 62th Annual Meeting, Society of Nuclear Medicine, 2015.06. |
| 19. | TAKURO ISODA, Shingo Baba, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Hiroshi Honda, Use of recombinant human thyroid-stimulating hormone (rhTSH) reduces the damage to salivary glands after radioiodine therapy for thyroid cancer, 62th Annual Meeting, Society of Nuclear Medicine, 2015.06. |
| 20. | Akifumi Yamada, Shingo Baba, TAKURO ISODA, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Hiroshi Honda, Effective synthesis of Pittsburg Compound B (11C-PIB) for clinical application by on-column 11C-methylation, 62th Annual Meeting, Society of Nuclear Medicine, 2015.06. |
| 21. | TAKURO ISODA, Shingo Baba, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Hiroshi Honda, Impact of the patient age on flip-flop phenomenon in lung metastasis from thyroid cancer, 27th European Congress of Radiology, 2015.05. |
| 22. | Shingo Baba, Takuro Isoda, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Hiroshi Honda, Usefulness of myocardial 123I-MIBG-SPECT for the differential diagnosis of Parkinson's syndrome, 61th Annual Meeting, Society of Nuclear Medicine, 2014.06. |
| 23. | Shingo Baba, Koichiro Abe, Takuro Isoda, Yasuhiro Maruoka, Masayuki Sasaki, Hiroshi Honda, Variability of size-collected pretreatment FDG uptake predicts prognosis of patients with diffuse large cell lymphoma., 59th Annual Meeting, Society of Nuclear Medicine, 2012.06, Purpose: To evaluate the usefulness of recovery-collected SUVs in the clinical diagnosis of malignant lymphoma patients. Materials and Methods: Previously reported recovery-collection using simple table look-up method was used in this study. Recovery coefficient was estimated using size and signal-background ratio by phantom experiment. Fifty three patients of malignant lymphoma (DLBCL; 37, FL; 16) were subjected to FDG-PET/CT for initial staging. Recovery-collected SUVs (SUVcor) were calculated and average±SD, coefficient of variation (CV) of SUVcor were compared with those of conventional SUV within the patient and between the groups divided by histology and prognosis. Result: Average±SD of SUVmax, SUVcor were higher in DLBCL (14.5±9.1, 18.6±9.6) than in FL(8.5±2.6, 11.7±3.24)( p<0.05). With recovery collection, average±SD was increased and CVs within the patient were significantly decreased in both type of histology(p<0.05). CVs of SUVcor was significantly smaller in good responder (20cases) than those of poor responder (17) (p<0.05). Conclusion: Uptakes of FDG free from partial-volume effect can be measured correctly with this method. Variability of pretreatment SUVs with size-collection is one of the independent predictor of the prognosis of patient with DLBCL. . |
| 24. | ariability of size-collected SUV evaluated by FDG-PET/CT predicts prognosis of patients with diffuse large cell lymphoma.. |
| 25. | , [URL]. |
| 26. | The 18F-FAZA /FDG uptake ratio: Potential Index of tumor hypoxia?. |
- Society of Nuclear Medicine
Educational
Unauthorized reprint of the contents of this database is prohibited.